New trial aims to stop thymic cancer return with Chemo-Radiation combo

NCT ID NCT06402708

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding chemotherapy to standard radiation after thymic cancer surgery can prevent the cancer from coming back. About 172 adults who had complete tumor removal will receive either radiation alone or radiation plus four cycles of chemotherapy (paclitaxel, cisplatin, 5-FU). Researchers will track how long participants stay cancer-free and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 212013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (paclitaxel, cisplatin, 5-FU, calcium folinate) plus radiotherapy

What this could lead to

If it works, this could show that adding chemotherapy after surgery helps prevent thymic cancer from coming back.

What could go wrong

This is a mid-stage trial with only 172 people, so results may not apply to everyone. Chemotherapy can cause side effects like low blood counts and fatigue.

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.